All In Biotech

Drug Trial Radar · NCT02854072

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

A Prospective, Randomized, Open-label, Multicenter, Parallel Design, Phase III Study to Assess the Efficacy and Safety of GV1001 Concurrent With Gemcitabine/Capecitabine Versus Gemcitabine/Capecitabine Alone in Treating Locally Advanced and Metastatic Pancreatic Cancer Patients

Last checked: Nov 19, 2026Latest source record: Nov 22, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

148

Planned (sponsor's estimate)

Start

Nov 2015

Primary completion

May 2018

Study completion May 2018

Sponsor

Sponsor type
Industry
First posted
Aug 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess treatment of GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in locally advanced and metastatic pancreatic cancer patients.

Conditions

  • Pancreatic Cancer

Interventions

  • GV1001Drug

    At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.

  • GemcitabineDrug

    Gemcitabine 1000 mg/m\^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.

  • CapecitabineDrug

    Capecitabine 830 mg/m\^2 will be orally given in the morning and evening (total dose of 1660 mg/m\^2) for 21 days followed by 7 days' rest.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: one year

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Pusan National University Hospital

    Busan, South Korea · Recruiting

  • Daegu Catholic University Medical Center

    Daegu, South Korea · Recruiting

  • Konyang University Hospital

    Daejeon, South Korea · Recruiting

  • Chonnam National University Hospital

    Gwangju, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • Gangnam Severance Hospital

    Seoul, South Korea · Recruiting

  • Hanyang University Seoul Hospital

    Seoul, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

  • Wonju Severance Christian Hospital

    Wŏnju, Gangwon-do, South Korea · Recruiting

  • National Cancer Center

    Goyang-si, Gyeonggi-do, South Korea · Recruiting

  • Jeju National University Hospital

    Jeju City, Jeju-do, South Korea · Recruiting

  • Chonbuk National University Hospital

    Jeonju, Jeollabuk-do, South Korea · Recruiting

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.